urb937 has been researched along with Neuralgia* in 2 studies
2 other study(ies) available for urb937 and Neuralgia
Article | Year |
---|---|
Brain permeant and impermeant inhibitors of fatty-acid amide hydrolase suppress the development and maintenance of paclitaxel-induced neuropathic pain without producing tolerance or physical dependence in vivo and synergize with paclitaxel to reduce tumor
Activation of cannabinoid CB Topics: Amidohydrolases; Analgesics; Animals; Antineoplastic Agents; Benzamides; Benzoxazines; Brain; Cannabinoids; Carbamates; Cell Line, Tumor; Cell Survival; Drug Synergism; Drug Tolerance; HEK293 Cells; Humans; Hyperalgesia; Male; Mice; Mice, Inbred C57BL; Morpholines; Naphthalenes; Neuralgia; Paclitaxel; Substance-Related Disorders | 2019 |
Brain-Permeant and -Impermeant Inhibitors of Fatty Acid Amide Hydrolase Synergize with the Opioid Analgesic Morphine to Suppress Chemotherapy-Induced Neuropathic Nociception Without Enhancing Effects of Morphine on Gastrointestinal Transit.
Opioid-based therapies remain a mainstay for chronic pain management, but unwanted side effects limit therapeutic use. We compared efficacies of brain-permeant and -impermeant inhibitors of fatty acid amide hydrolase (FAAH) in suppressing neuropathic pain induced by the chemotherapeutic agent paclitaxel. Paclitaxel produced mechanical and cold allodynia without altering nestlet shredding or marble burying behaviors. We compared FAAH inhibitors that differ in their ability to penetrate the central nervous system for antiallodynic efficacy, pharmacological specificity, and synergism with the opioid analgesic morphine. (3'-(aminocarbonyl)[1,1'-biphenyl]- 3-yl)-cyclohexylcarbamate (URB597), a brain-permeant FAAH inhibitor, attenuated paclitaxel-induced allodynia via cannabinoid receptor 1 (CB Topics: Amidohydrolases; Analgesics, Opioid; Animals; Antineoplastic Agents; Arachidonic Acids; Benzamides; Brain; Cannabinoids; Carbamates; Gastrointestinal Transit; Hyperalgesia; Indoles; Mice; Mice, Inbred C57BL; Morphine; Morpholines; Neuralgia; Nociception; Piperidines; Pyrazoles; Receptor, Cannabinoid, CB1; Receptor, Cannabinoid, CB2 | 2018 |